Clinical conditions related to LVADs that may arise during hemodialysis #Nephpearls #NephSky 👉 link.springer.com/book/10.1007...
Edgar V. Lerma 🇵🇭
@edgarvlermamd.medsky.network
Chicago Sports Fan... Nephrologist by day. My tweets are not medical advice. The views expressed here are my own and not those of my employer
Call 📢 for papers: "The Jerry Yee: Clinical Challenges in Diagnosis and Treatment in Nephrology" #Nephpearls #NephSky 🗓️ Deadline for submissions: 15 October 2026 👉 www.sciencedirect.com/special-issu...
Impact of proteinuria levels on long-term kidney outcomes in IgA nephropathy: a meta-analysis ca. 2026 from @glomcon.org Rare Kidney Disease journal #Nephpearls #NephSky 👉🏼 link.springer.com/article/10.1...
Ten tips for the diagnosis and management of nephrotic syndrome ca. 2026 #Nephpearls #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/42707999/
Classic course of whole-kidney GFR and UAE according to the natural (proteinuric) pathway of #Diabetic #Kidney Disease (DKD) ca. 2017 #Nephpearls #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/28143897/
Adults with #IgAN are at greater risk of adverse kidney outcomes versus nonglomerular CKD and substantially higher risks of heart failure and death compared with no CKD ca. 2026 from @KIReports #Nephpearls #RKDSummit #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/42027552/
Not all #IgAN therapies are created equal #Nephpearls #RKDSummit #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/40928891/
Dipstick hemoglobinuria is associated with histologic markers of active disease in #IgAN and may provide clinically relevant information to complement current assessment of disease activity in #IgAN ca. 2026 #Nephpearls #RKDSummit #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/42628835/
Microscopic hematuria as a risk factor for #IgAN progression: considering this biomarker in selecting and monitoring patients ca. 2023 #Nephpearls #RKDSummit #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/38053974/
Targeting B cells in immune-mediated kidney diseases: conclusions from @kdigo.org Controversies Conference ca. 2026 #Nephpearls #RKDSummit #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/42034308/
Thank you for the kind words and the wonderful hospitality! It was an absolute honor to present at the Renal Research Forum and engage with such a fantastic group of colleagues at Mayo Clinic 🙏 #NephSky
Leticia Rolon, MD@leticiarolonmd.bsky.social · 3w agoHonored to have Dr. Edgar Lerma @edgarvlermamd.medsky.network presenting at our Mayo Clinic Nephrology Renal Research Forum speaking on Evidence-Based Management of Inpatient Hypertension & Utilizing Social Media for Nephrology Education. Truly a pioneer in #MedEd 🩺🫘
Kidney Health Guidance on Cardiovascular-Kidney-Metabolic (CKM) Syndrome ca. 2026 from @asnpublications.bsky.social #Nephpearls #NephSky #Cardiorenal 👉 pubmed.ncbi.nlm.nih.gov/42684397/
Syndrome of Inappropriate Antidiuresis (SIAD): From Pathophysiology to Management ca. 2023 #Nephpearls #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/36974717/
Lower Time Averaged-Proteinuria (TA-P) was associated with progressively reduced risk of kidney failure in adults with IgA Nephropathy #IgAN in the US ca. 2026 from @glomcon.org Rare Kidney Disease Journal #Nephpearls #NephSky 👉 link.springer.com/article/10.1...
In ADPKD, probenecid reduced tolvaptan-induced polyuria and nocturia while preserving its disease-modifying effects 🔑 A potential strategy to make tolvaptan more tolerable - and a new window into renal water homeostasis #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42298327/
Phase 3 proteinuria and eGFR data for available and emerging IgA Nephropathy #IgAN therapeutics (as of August 3, 2026) #Nephpearls #GlomConHawaii 🌊 #NephSky 👉 pubmed.ncbi.nlm.nih.gov/41895685/
VISIONARY: Sibeprenlimab in IgA nephropathy #IgAN ✅ Proteinuria reduction ✅ Preservation of kidney function #Nephpearls #GlomConHawaii 🌊 #NephSky #VisualAbstract by @alexgr23.bsky.social
nsMRAs in CKM Syndrome: Disease-Specific Deep Dives www.medscape.org/viewarticle/... via @MedscapeCME #Nephpearls #NephSky
Targeting BAFF and APRIL in IgA Nephropathy reachmd.com/programs/fro... via @ReachMD #Nephpearls #NephSky
Targeting BAFF and APRIL in IgA Nephropathy
Advances in our understanding of BAFF and APRIL biology are reshaping the treatment landscape for IgA nephropathy (IgAN), with dual pathway inhibition emerging as a promising disease-modifying strateg...
reachmd.com
Urea vs. tolvaptan for hospitalized patients with SIADH ca. 2026 #Nephpearls #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/42455009/
Kick, Sweat, Protect: Kidney Health Through the Lens of Soccer (Football) ca. 2026 #Nephpearls #WorldCup #WorldCup2026 #NephSky 👉🏼 www.kidneymedicinejournal.org/article/S259...
Enthusiasm for EGDT has waned as 3 large, multicenter trials failed to reproduce the results of the Rivers trial #Nephpearls #AKIinICU #NephSky 🔑 Current Surviving Sepsis guidelines recommend an initial bolus of 30 mL/kg to be followed by additional fluid to maintain and improve perfusion
Obesity in CKD: Treatment algorithm ca. 2026 from @ndt-era.bsky.social @saynanorouzi.bsky.social @rahaai.bsky.social #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/42446420/
The kidney in the middle: @kdigo.org guidelines address multiple key components of cardiovascular-kidney-metabolic syndrome ca. 2026 from @Kidney_Int #Nephpearls #Cardiorenal #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/42191113/
When shock is refractory to initial fluid resuscitation, it is appropriate to consider vasopressor support #Nephpearls #AKIinICU #NephSky 📌 Distributive shock requires alpha-adrenergic stimulation to promote vasoconstriction and raise SVR
Screening algorithms in septic shock #Nephpearls #AKIinICU #NephSky ⚠️ SIRS may be highly sensitive but lacks specificity ⚠️ qSOFA may lack sensitivity for early sepsis or septic shock 🔑 These limitations highlight the importance of high clinical suspicion for shock 👉 shop.lww.com/Handbook-of-...
The fundamental problem in shock is "inadequate end-organ perfusion" #Nephpearls #AKIinICU #NephSky 📌 Low cardiac output (CO) ✔️ Hypovolemic ✔️ Cardiogenic ✔️ Obstructive 📌 Low systemic vascular resistance (SVR) aka Distributive: Sepsis
